MDGL FY 2011 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2011 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-48.8% YoY

Gross Profit

$6M80.7% margin

Operating Income

-$45M-599.1% margin

Net Income

-$47M-624.7% margin

EPS (Diluted)

$-35.14

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$48M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$42M

Total Liabilities

$28M

Stockholders' Equity

$15M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$15M	-48.8%
Gross Profit	$6M	$0	—
Operating Income	-$45M	-$37M	-23.1%
Net Income	-$47M	-$37M	-26.5%